866-997-4948(US-Canada Toll Free)

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Oct 2017

Category :

Pharmaceutical

No. of Pages : 75 Pages

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Pipeline Review, H2 2017

Summary

According to the recently published report 'Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform - Pipeline Review, H2 2017'; Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit beta isoform is an enzyme encoded by the PIK3CB gene. It is involved in cell growth, survival, proliferation, motility and morphology. It participates in cellular signaling in response to various growth factors. It is involved in the activation of AKT1 and signaling via insulin-receptor substrate (IRS) proteins. It is required for lymphatic vasculature development, different signaling pathways for stable platelet adhesion and aggregation. It plays an important role in platelet activation.

The report 'Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform - Pipeline Review, H2 2017' outlays comprehensive information on the Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 4, 3 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System, Dermatology and Ophthalmology which include indications Solid Tumor, Breast Cancer, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Glioblastoma Multiforme (GBM), Lymphoma, Ovarian Cancer, Follicular Lymphoma, Head And Neck Cancer Squamous Cell Carcinoma, Multiple Myeloma (Kahler Disease), Neuroblastoma, Pancreatic Cancer, Prostate Cancer, Refractory Chronic Lymphocytic Leukemia (CLL), Thyroid Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Anaplastic Thyroid Cancer, Burkitt Lymphoma, CNS Lymphoma, Colorectal Cancer, Gastric Cancer, Gastrointestinal Stromal Tumor (GIST), Hepatocellular Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Lung Cancer, Mantle Cell Lymphoma, Melanoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Myelofibrosis, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Papillary Thyroid Cancer, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary CNS Lymphoma, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Cell Carcinoma, Squamous Non-Small Cell Lung Cancer, Thrombocythemia Myelofibrosis, Thrombosis and Thymoma (Thymic Epithelial Tumor).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153)
- The report reviews Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) targeted therapeutics and enlists all their major and minor projects
- The report assesses Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Overview 7
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Therapeutics Development 8
Products under Development by Stage of Development 8
Products under Development by Therapy Area 9
Products under Development by Indication 10
Products under Development by Companies 14
Products under Development by Universities/Institutes 20
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Therapeutics Assessment 22
Assessment by Mechanism of Action 22
Assessment by Route of Administration 23
Assessment by Molecule Type 24
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Companies Involved in Therapeutics Development 25
AstraZeneca Plc 25
Bayer AG 25
Curis Inc 26
GlaxoSmithKline Plc 27
Karus Therapeutics Ltd 27
Novartis AG 28
PIQUR Therapeutics AG 29
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Drug Profiles 31
AZD-8186 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
BAY-1082439 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Bimiralisib - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
buparlisib hydrochloride - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
fimepinostat - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
GSK-2636771 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
KA-2237 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
MIPS-9922 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
PQR-514 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
PQR-530 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
SF-2523 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Small Molecule to Inhibit PI3K for Prostate Cancer - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Small Molecules to Inhibit Pan PI3K for Ovarian Cancer - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Dormant Products 60
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Discontinued Products 62
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Product Development Milestones 63
Featured News & Press Releases 63
Sep 25, 2017: SignalRx Presents in silico Design of Dual PI3K/BRD4 Inhibitors for Combinatorial Activation of Anti-tumor Immunity in Treating Cancer 63
May 25, 2017: Curis Announces Presentation Related to CUDC-907 at 2017 ASCO Annual Meeting 63
May 01, 2017: SignalRx Discloses its Novel Immuno-Oncology Program Approach at the 12th Annual Drug Discovery Chemistry 2017 Meeting 64
Apr 27, 2017: PIQUR Receives EMA Orphan Drug Designation for PQR309 in Diffuse Large B-Cell Lymphoma 64
Feb 01, 2017: SignalRx Pharmaceuticals Announces Breakthrough Results on Novel Anti-Cancer Dual PI3K-BRD4 Inhibition Paradigm in PNAS Publication 65
Dec 12, 2016: PI3K Inhibitor Buparlisib in Combination with Fulvestrant Prolongs PFS Compared to Placebo Plus Fulvestrant 66
Oct 05, 2016: Karus Therapeutics Announces First Lymphoma Patients Dosed with KA2237 in Clinical Study at the MD Anderson Cancer Center 67
Jun 08, 2016: Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association 68
Jun 02, 2016: Curis Announces Presentations Related to CUDC-907 at 2016 ASCO Annual Meeting 68
Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CUDC-907 at AACR Annual Meeting 68
Apr 04, 2016: Curis Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology 69
Jan 11, 2016: Seahorse Bioscience XF Technology Reaches 500th Citation in Cancer Research 69
Dec 06, 2015: Curis Reports Clinical Activity of CUDC-907 in Patients With DLBCL Harboring MYC Oncogene Alterations at the 2015 ASH Annual Meeting 70
Nov 05, 2015: Curis Announces Oral Presentation of Phase 1 Data for CUDC-907 at 2015 ASH Annual Meeting 72
Jun 10, 2015: Curis to Present CUDC-907 Clinical Data at the 20th Congress of the European Hematology Association and the 13th International Congress on Malignant Lymphoma 72
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 74
Disclaimer 75

List of Tables
Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Indications, H2 2017 10
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 12
Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 13
Number of Products under Development by Companies, H2 2017 14
Products under Development by Companies, H2 2017 15
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 16
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 17
Products under Development by Companies, H2 2017 (Contd..3), H2 2017 18
Products under Development by Companies, H2 2017 (Contd..4), H2 2017 19
Number of Products under Investigation by Universities/Institutes, H2 2017 20
Products under Investigation by Universities/Institutes, H2 2017 21
Number of Products by Stage and Mechanism of Actions, H2 2017 22
Number of Products by Stage and Route of Administration, H2 2017 23
Number of Products by Stage and Molecule Type, H2 2017 24
Pipeline by AstraZeneca Plc, H2 2017 25
Pipeline by Bayer AG, H2 2017 26
Pipeline by Curis Inc, H2 2017 26
Pipeline by GlaxoSmithKline Plc, H2 2017 27
Pipeline by Karus Therapeutics Ltd, H2 2017 28
Pipeline by Novartis AG, H2 2017 29
Pipeline by PIQUR Therapeutics AG, H2 2017 30
Dormant Products, H2 2017 60
Dormant Products, H2 2017 (Contd..1), H2 2017 61
Discontinued Products, H2 2017 62

List of Figures
Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Top 10 Indications, H2 2017 10
Number of Products by Stage and Mechanism of Actions, H2 2017 22
Number of Products by Stage and Route of Administration, H2 2017 23
Number of Products by Stage and Molecule Type, H2 2017 24

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *